Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifamycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 4/20 | 0.70 |
| ▸ | ABCC2 | Q92887 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifamycin SCHEMBL22389512 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL31715824 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29355202 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL182452 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL151824 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL23370269 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29649054 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL22553368 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL22389517 | 0.99 | ABCB11 (0.99) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29816867 | 0.99 | ABCB11 (0.99) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20550 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075482-A | Use of rifamycin in the treatment of colorectal cancer | — | 2026-05-26 | — | — | CN | claimed |
| CN-122080018-A | Synthetic process for preparing rifampicin by using rifamycin O as starting material | — | 2026-05-26 | — | — | CN | claimed |
| EP-4057998-B1 | PROCESS FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR ORAL INTAKE AND DRUG RELEASE IN THE COLON | ETHYPHARM SA (FR) | 2026-05-13 | — | — | EP | claimed |
| US-20260124213-A1 | STAPHYLOCOCCUS AUREUS PBP4 INHIBITORS AND METHOD OF USE | UNIV ROCHESTER (US) | 2026-05-07 | — | — | US | claimed |
| US-12616708-B2 | Methods for treating pulmonary non-tuberculous mycobacterial infections | INSMED INCORPORATED (US) | 2026-05-05 | — | — | US | claimed |
| US-20260109712-A1 | RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA | UNIV MINNESOTA (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108489-A1 | TOPICAL NASAL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF CHRONIC RHINOSINUSITIS (CRS) | VARIZAT EDUARDO ROBERTO (AR) | 2026-04-23 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| EP-4698240-A1 | ANTIMICROBIAL COMPOSITIONS AND SUTURES COATED THEREWITH | Covidien LP (US) | 2026-02-25 | — | — | EP | claimed |
| US-4144234-A | Preparation of rifamycin P and Q derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1979-03-13 | — | — | US | claimed |
| US-4124585-A | Rifamycin compounds | ARCHIFAR LABORATORI CHIMICO FARMACOLOGICI S.P.A. (IT) | 1978-11-07 | — | — | US | claimed |
| US-4124586-A | Rifamycin compounds | ARCHIFAR LABORATORI CHIMICO FARMACOLOGICI S.P.A. (IT) | 1978-11-07 | — | — | US | claimed |
| US-4116957-A | ANTIBIOTIC, ANTIBACTERIAL | ARCHIFAR INDUSTRIE CHIMICHE DEL TRENTINO S.P.A. (IT) | 1978-09-26 | — | — | US | claimed |
| US-4100276-A | BACTERICIDES, MICROBIOCIDES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1978-07-11 | — | — | US | claimed |
| US-4086225-A | Rifamycin compounds | ARCHIFAR INDUSTRIE CHIMICHE DEL TRENTINO S.P.A. (IT) | 1978-04-25 | — | — | US | claimed |
| US-4060606-A | 16-SULFIDES OR SULFOXIDES, STEROIDS, ANTIBACTERIAL | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1977-11-29 | — | — | US | claimed |
| US-4024871-A | POLYURETHANE | ETHICON, INC. (US) | 1977-05-24 | — | — | US | claimed |
| US-4017481-A | Rifamycin compounds | ARCHIFAR INDUSTRIE CHIMICHE DEL TRENTINO S.P.A. (IT) | 1977-04-12 | — | — | US | claimed |
| US-3987797-A | ANTIMICROBIAL SUTURES | ETHICON, INC. (US) | 1976-10-26 | — | — | US | claimed |